Pegfilgrastim
Brand names: Armlupeg · Active ingredient: Pegfilgrastim
In short: Armlupeg is indicated in adults and pediatric patients aged newborn and older to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of feb
What is Pegfilgrastim used for?
Armlupeg is indicated in adults and pediatric patients aged newborn and older to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia .
Limitations of Use
Armlupeg is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.
Armlupeg is indicated to increase survival in adults and pediatric patients aged newborn and older acutely exposed to myelosuppressive doses of radiation .
Pegfilgrastim dosage
The recommended dosage of Armlupeg for adults of any weight and pediatric patients weighing at least 45 kg with cancer receiving myelosuppressive chemotherapy is a single subcutaneous injection of 6 mg administered once per chemotherapy cycle. Do not administer Armlupeg between 14 days before and 24 hours after administration of chemotherapy.
The recommended dosage of Armlupeg for adults of any weight and pediatric patients weighing at least 45 kg with hematopoietic subsyndrome of acute radiation syndrome is two doses, 6 mg each, administered subcutaneously one week apart. Administer the first dose as soon as possible after suspected or confirmed exposure to radiation levels greater than 2 gray (Gy). Administer the second dose one week after the first dose.
Obtain a baseline complete blood count (CBC). Do not delay administration of Armlupeg if a CBC is not readily available. Estimate a patient's absorbed radiation dose (i.e., level of radiation exposure) based on information from public health authorities, biodosimetry if available, or clinical findings such as time to onset of vomiting or lymphocyte depletion kinetics.
Armlupeg is supplied in single-dose prefilled syringes for manual use .
Before using Armlupeg:
Remove the carton from the refrigerator and allow the Armlupeg prefilled syringe to reach room temperature, 20℃ to 25℃ (68℉ to 77℉), for a minimum of 30 minutes. Do not warm in any other way. Discard any prefilled syringe left at room temperature for greater than 48 hours.
Armlupeg is a clear, colorless, preservative-free solution. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not administer Armlupeg if discoloration or particulates are observed.
Prefilled Syringe for Manual Use
For adult patients of any weight and pediatric patients weighing 45 kg and greater, the single-dose prefilled syringe for manual use is intended for subcutaneous administration of a single 6 mg/0.6 mL dose of Armlupeg. The syringe does not bear graduation marks and therefore does not allow for direct administration of doses less than 6 mg/0.6 mL. There is no presentation for Armlupeg that allows weight-based dosing for pediatric patients below 45 kg.
The needle cap on the prefilled syringe contains dry natural rubber (derived from latex); persons with latex allergies should not administer this product.
How to take Pegfilgrastim — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use).
Advise patients of the following risks and potential risks with Armlupeg:
Splenic rupture and splenomegaly
Acute Respiratory Distress Syndrome
Serious hypersensitivity reactions
Sickle cell crisis
Glomerulonephritis
Increased risk of Myelodysplastic Syndrome and/or Acute Myeloid Leukemia in patients with breast and lung cancer who receive Armlupeg in conjunction with chemotherapy and/or radiation therapy.
Capillary Leak Syndrome
Large and medium vessel arteritis, including aortitis.
Advise patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome) that efficacy studies of pegfilgrastim products for this indication could not be conducted in humans for ethical and feasibility reasons and that, therefore, approval of this use was based on efficacy studies conducted in animals .
Instruct patients who self-administer Armlupeg using the single-dose prefilled syringe of the:
Importance of following the Instructions for Use.
Dangers of reusing syringes. …
Warnings & precautions
Do not take this medicine if: Armlupeg is contraindicated in patients with a history of a serious hypersensitivity reaction to pegfilgrastim products or filgrastim products. Reactions have included anaphylaxis .
Splenic rupture, including fatal cases, can occur following the administration of pegfilgrastim products. Evaluate for an enlarged spleen or splenic rupture in patients who report left upper abdominal or shoulder pain after receiving Armlupeg.
Acute respiratory distress syndrome (ARDS) can occur in patients receiving pegfilgrastim products. Evaluate patients who develop fever and lung infiltrates or respiratory distress after receiving Armlupeg, for ARDS. Discontinue Armlupeg in patients with ARDS.
Serious hypersensitivity reactions, including anaphylaxis, can occur in patients receiving pegfilgrastim products. The majority of reported events occurred upon initial exposure. Hypersensitivity reactions, including anaphylaxis, can recur within days after the discontinuation of initial therapies to manage the reaction. Permanently discontinue Armlupeg in patients with serious hypersensitivity reactions. Armlupeg is contraindicated in patients with a history of a serious hypersensitivity reaction to pegfilgrastim products or filgrastim products.
Severe and sometimes fatal sickle cell crises can occur in patients with sickle cell disorders receiving pegfilgrastim products. Discontinue Armlupeg if sickle cell crisis occurs.
Glomerulonephritis has occurred in patients receiving pegfilgrastim products. The diagnoses were based upon azotemia, hematuria (microscopic and macroscopic), proteinuria, and renal biopsy. Generally, events of glomerulonephritis resolved after dose‑reduction or discontinuation of pegfilgrastim products. If glomerulonephritis is suspected, evaluate for cause. If causality is likely, consider dose-reduction or interruption of Armlupeg. …
Pegfilgrastim side effects
The following clinically significant adverse reactions are discussed in greater detail in other sections of the labeling:
Splenic Rupture
Acute Respiratory Distress Syndrome
Serious Hypersensitivity Reactions
Use in Patients with Sickle Cell Disorders
Glomerulonephritis
Leukocytosis
Thrombocytopenia
Capillary Leak Syndrome
Potential for Tumor Growth Stimulatory Effects on Malignant Cells
Myelodysplastic syndrome
Acute myeloid leukemia
Large and medium vessel arteritis, including aortitis
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
Pegfilgrastim clinical trials safety data are based upon 932 patients receiving pegfilgrastim in seven randomized clinical trials. The population was 21 to 88 years of age and 92% female. The ethnicity was 75% Caucasian, 18% Hispanic, 5% Black, and 1% Asian. Patients with breast (n=823), lung and thoracic tumors (n=53) and lymphoma (n=56) received pegfilgrastim after nonmyeloablative cytotoxic chemotherapy. Most patients received a single 100 mcg/kg (n=259) or a single 6 mg (n= 546) dose per chemotherapy cycle over 4 cycles. …
About this medicine
Pegfilgrastim-unne is a covalent conjugate of recombinant methionyl human G-CSF and monomethoxypolyethylene glycol. Recombinant methionyl human G-CSF is a water-soluble 175 amino acid protein with a molecular weight of approximately 19 kilodaltons (kD). Recombinant methionyl human G-CSF is obtained from the bacterial fermentation of a strain of E coli transformed with a genetically engineered plasmid containing the human G-CSF gene. To produce pegfilgrastim-unne, a 20 kD monomethoxypolyethylene glycol molecule is covalently bound to the N-terminal methionyl residue of recombinant methionyl human G-CSF. The average molecular weight of pegfilgrastim-unne is approximately 39 kD.
Armlupeg (pegfilgrastim-unne) injection is a sterile, clear, colorless, preservative-free solution intended for subcutaneous use only and is supplied in a single-dose prefilled syringe with a 27‑gauge ½" needle and rigid needle shield, with UltraSafe Plus PassiveTM Needle Guard. The prefilled syringe does not bear graduation marks and is designed to deliver the entire contents of the syringe (6 mg/0.6 mL). …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID c48fe1a7-63d7-4dce-bb53-a913cb0ade83. Read the full official label on DailyMed.
Related medicines
Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate